Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
25 Apr 24
8-K
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
25 Apr 24
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
8-K
Departure of Directors or Certain Officers
19 Apr 24
8-K
Regulation FD Disclosure
17 Apr 24
SC TO-I/A
Issuer tender offer statement (amended)
27 Mar 24
8-K
Departure of Directors or Certain Officers
26 Mar 24
SC TO-I/A
Issuer tender offer statement (amended)
21 Feb 24
SC TO-I/A
Issuer tender offer statement (amended)
14 Feb 24
S-8
Registration of securities for employees
14 Feb 24
10-K
2023 FY
Annual report
14 Feb 24
8-K
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
14 Feb 24
SC TO-I/A
Issuer tender offer statement (amended)
31 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
31 Jan 24
8-K
Entry into a Material Definitive Agreement
24 Jan 24
SC TO-I
Issuer tender offer statement
23 Jan 24
8-K
Departure of Directors or Certain Officers
8 Jan 24
DEFA14A
Additional proxy soliciting materials
19 Dec 23
DEF 14A
Definitive proxy
19 Dec 23
SC TO-C
Information about tender offer
8 Dec 23
PRE 14A
Preliminary proxy
8 Dec 23
8-K
Entry into a Material Definitive Agreement
7 Nov 23
424B5
Prospectus supplement for primary offering
7 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
7 Nov 23
8-K
Cost Associated with Exit or Disposal Activities
31 Aug 23
S-8
Registration of securities for employees
7 Aug 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
7 Aug 23
8-K
Departure of Directors or Certain Officers
16 Jun 23
DEFA14A
Additional proxy soliciting materials
7 Jun 23
10-Q
2023 Q1
Quarterly report
2 May 23
8-K
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
2 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
8-K
Departure of Directors or Certain Officers
16 Mar 23
S-8
Registration of securities for employees
16 Feb 23
Latest ownership filings
4
Barry E Greene
15 Feb 24
4
Anne Marie Cook
15 Feb 24
4
Laura Gault
15 Feb 24
4
Christopher Benecchi
15 Feb 24
4
KIMI IGUCHI
15 Feb 24
SC 13G
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BB BIOTECH AG
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
SC 13G
STATE STREET CORP
24 Jan 24
4
Jessica Federer
4 Jan 24
4
STEVEN M PAUL
4 Jan 24
4
JAMES M FRATES
4 Jan 24
4
George Golumbeski
4 Jan 24
4
KIMI IGUCHI
4 Jan 24
4
JEFFREY M JONAS
30 Nov 23
4
KIMI IGUCHI
30 Nov 23
4
Anne Marie Cook
30 Nov 23
4
Elizabeth Barrett
11 Aug 23
4
Barry E Greene
8 Aug 23
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
10 Jul 23
4
Jessica Federer
16 Jun 23
4
Elizabeth Barrett
16 Jun 23
4
JAMES M FRATES
16 Jun 23
4
JEFFREY M JONAS
16 Jun 23
4
STEVEN M PAUL
16 Jun 23
4
Geno J Germano
16 Jun 23
4
George Golumbeski
16 Jun 23
4
KEVIN P STARR
16 Jun 23
4
MICHAEL F COLA
16 Jun 23
4
Elizabeth Barrett
11 May 23
3
Jessica Federer
17 Mar 23
4
Jessica Federer
17 Mar 23
4
KIMI IGUCHI
17 Mar 23
4
KIMI IGUCHI
23 Feb 23
SC 13G
BB BIOTECH AG
17 Feb 23
4
Laura Gault
15 Feb 23
4
Anne Marie Cook
15 Feb 23